175 related articles for article (PubMed ID: 23954705)
1. MALDI-MS tissue imaging identification of biliverdin reductase B overexpression in prostate cancer.
Pallua JD; Schaefer G; Seifarth C; Becker M; Meding S; Rauser S; Walch A; Handler M; Netzer M; Popovscaia M; Osl M; Baumgartner C; Lindner H; Kremser L; Sarg B; Bartsch G; Huck CW; Bonn GK; Klocker H
J Proteomics; 2013 Oct; 91():500-14. PubMed ID: 23954705
[TBL] [Abstract][Full Text] [Related]
2. MALDI MS profiling of post-DRE urine samples highlights the potential of β-microseminoprotein as a marker for prostatic diseases.
Flatley B; Wilmott KG; Malone P; Cramer R
Prostate; 2014 Jan; 74(1):103-11. PubMed ID: 24115268
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer.
Malik G; Ward MD; Gupta SK; Trosset MW; Grizzle WE; Adam BL; Diaz JI; Semmes OJ
Clin Cancer Res; 2005 Feb; 11(3):1073-85. PubMed ID: 15709174
[TBL] [Abstract][Full Text] [Related]
4. Proteomics profiling of microdissected low- and high-grade prostate tumors identifies Lamin A as a discriminatory biomarker.
Skvortsov S; Schäfer G; Stasyk T; Fuchsberger C; Bonn GK; Bartsch G; Klocker H; Huber LA
J Proteome Res; 2011 Jan; 10(1):259-68. PubMed ID: 20977276
[TBL] [Abstract][Full Text] [Related]
5. The expression profile of phosphatidylinositol in high spatial resolution imaging mass spectrometry as a potential biomarker for prostate cancer.
Goto T; Terada N; Inoue T; Nakayama K; Okada Y; Yoshikawa T; Miyazaki Y; Uegaki M; Sumiyoshi S; Kobayashi T; Kamba T; Yoshimura K; Ogawa O
PLoS One; 2014; 9(2):e90242. PubMed ID: 24587297
[TBL] [Abstract][Full Text] [Related]
6. Dietary influences on tissue concentrations of phytanic acid and AMACR expression in the benign human prostate.
Kataria Y; Wright M; Deaton RJ; Rueter EE; Rybicki BA; Moser AB; Ananthanrayanan V; Gann PH
Prostate; 2015 Feb; 75(2):200-10. PubMed ID: 25307752
[TBL] [Abstract][Full Text] [Related]
7. Zonal regulation of collagen-type proteins and posttranslational modifications in prostatic benign and cancer tissues by imaging mass spectrometry.
Angel PM; Spruill L; Jefferson M; Bethard JR; Ball LE; Hughes-Halbert C; Drake RR
Prostate; 2020 Sep; 80(13):1071-1086. PubMed ID: 32687633
[TBL] [Abstract][Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
9. Isolation of human prostatic epithelial plasma membranes for proteomics using mirror image tissue banking of radical prostatectomy specimens.
Sircar K; Gaboury L; Ouadi L; Mecteau M; Scarlata E; Saad F; Aprikian A; Tanguay S; Lapointe S; Lussier C; Miletti T; Lanoix J
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4178-84. PubMed ID: 16857789
[TBL] [Abstract][Full Text] [Related]
10. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
11. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.
Nariculam J; Freeman A; Bott S; Munson P; Cable N; Brookman-Amissah N; Williamson M; Kirby RS; Masters J; Feneley M
Asian J Androl; 2009 Jan; 11(1):109-18. PubMed ID: 19050681
[TBL] [Abstract][Full Text] [Related]
12. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.
Rubin MA; Zhou M; Dhanasekaran SM; Varambally S; Barrette TR; Sanda MG; Pienta KJ; Ghosh D; Chinnaiyan AM
JAMA; 2002 Apr; 287(13):1662-70. PubMed ID: 11926890
[TBL] [Abstract][Full Text] [Related]
13. Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements.
Rubin MA; Zerkowski MP; Camp RL; Kuefer R; Hofer MD; Chinnaiyan AM; Rimm DL
Am J Pathol; 2004 Mar; 164(3):831-40. PubMed ID: 14982837
[TBL] [Abstract][Full Text] [Related]
14. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Luo J; Zha S; Gage WR; Dunn TA; Hicks JL; Bennett CJ; Ewing CM; Platz EA; Ferdinandusse S; Wanders RJ; Trent JM; Isaacs WB; De Marzo AM
Cancer Res; 2002 Apr; 62(8):2220-6. PubMed ID: 11956072
[TBL] [Abstract][Full Text] [Related]
15. MALDI mass spectrometric imaging based identification of clinically relevant signals in prostate cancer using large-scale tissue microarrays.
Steurer S; Borkowski C; Odinga S; Buchholz M; Koop C; Huland H; Becker M; Witt M; Trede D; Omidi M; Kraus O; Bahar AS; Seddiqi AS; Singer JM; Kwiatkowski M; Trusch M; Simon R; Wurlitzer M; Minner S; Schlomm T; Sauter G; Schlüter H
Int J Cancer; 2013 Aug; 133(4):920-8. PubMed ID: 23381989
[TBL] [Abstract][Full Text] [Related]
16. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
Schostak M; Miller K; Krause H; Schrader M; Kempkensteffen C; Kollermann J
Cancer Detect Prev; 2006; 30(5):449-54. PubMed ID: 17067752
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Time-Resolved Fluorescence Imaging of Androgen Receptor and Prostate-Specific Antigen in Prostate Tissue Sections.
Krzyzanowska A; Lippolis G; Helczynski L; Anand A; Peltola M; Pettersson K; Lilja H; Bjartell A
J Histochem Cytochem; 2016 May; 64(5):311-22. PubMed ID: 27026295
[TBL] [Abstract][Full Text] [Related]
18. Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform.
Ummanni R; Mundt F; Pospisil H; Venz S; Scharf C; Barett C; Fälth M; Köllermann J; Walther R; Schlomm T; Sauter G; Bokemeyer C; Sültmann H; Schuppert A; Brümmendorf TH; Balabanov S
PLoS One; 2011 Feb; 6(2):e16833. PubMed ID: 21347291
[TBL] [Abstract][Full Text] [Related]
19. Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker.
Lemaire R; Menguellet SA; Stauber J; Marchaudon V; Lucot JP; Collinet P; Farine MO; Vinatier D; Day R; Ducoroy P; Salzet M; Fournier I
J Proteome Res; 2007 Nov; 6(11):4127-34. PubMed ID: 17939699
[TBL] [Abstract][Full Text] [Related]
20. Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer.
Hoogland AM; Böttcher R; Verhoef E; Jenster G; van Leenders GJ
Oncotarget; 2016 Jun; 7(25):37846-37856. PubMed ID: 27191985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
